Literature DB >> 10732833

Type 1 diabetes mellitus caused by treatment with interferon-beta.

S Kado1, J Miyamoto, N Komatsu, Y Iwaki, H Ozaki, H Taguchi, M Kure, G Sarashina, T Watanabe, Y Katsura, Y Nemoto, M Noritake, T Matsuoka.   

Abstract

A 57-year-old man was referred to our outpatient clinic after interferon-beta (IFN-beta) treatment for 7 weeks. While IFN-beta therapy was continued in our outpatient clinic, his blood glucose level increased gradually, and he was admitted to our hospital for hyperglycemia. The patient was prescribed a 1,600-kcal diet and intensive insulin therapy was performed. GAD antibody became positive 15 months after the start of IFN therapy, and disappeared 27 months after the start of IFN therapy. Insulin secretion was depleted and the patient had HLA-DR4, B54, and DRB1*0405. This appears to be a case of type 1 diabetes mellitus induced by administration of IFN-beta alone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10732833     DOI: 10.2169/internalmedicine.39.146

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  5 in total

1.  Dysregulated TLR3-dependent signaling and innate immune activation in superoxide-deficient macrophages from nonobese diabetic mice.

Authors:  Maria C Seleme; Weiqi Lei; Ashley R Burg; Kah Yong Goh; Allison Metz; Chad Steele; Hubert M Tse
Journal:  Free Radic Biol Med       Date:  2012-02-04       Impact factor: 7.376

Review 2.  Hepatitis C virus infection and type 1 and type 2 diabetes mellitus.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Dilia Giuggioli; Andrea Di Domenicantonio; Ilaria Ruffilli; Alda Corrado; Silvia Fabiani; Santino Marchi; Clodoveo Ferri; Ele Ferrannini; Poupak Fallahi
Journal:  World J Diabetes       Date:  2014-10-15

3.  A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models.

Authors:  Pär G Larsson; Tadepally Lakshmikanth; Olli H Laitinen; Renata Utorova; Stella Jacobson; Maarit Oikarinen; Erna Domsgen; Minni R L Koivunen; Pascal Chaux; Nicolas Devard; Valerie Lecouturier; Jeffrey Almond; Mikael Knip; Heikki Hyöty; Malin Flodström-Tullberg
Journal:  Diabetologia       Date:  2014-11-05       Impact factor: 10.122

4.  Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1.

Authors:  Anthony Meager; Kumuthini Visvalingam; Pärt Peterson; Kaidi Möll; Astrid Murumägi; Kai Krohn; Petra Eskelin; Jaakko Perheentupa; Eystein Husebye; Yoshihisa Kadota; Nick Willcox
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

Review 5.  Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment.

Authors:  Brittney N Newby; Clayton E Mathews
Journal:  Front Endocrinol (Lausanne)       Date:  2017-09-14       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.